Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms ...
While medication can provide symptom relief, it does not necessarily address underlying maladaptive behaviors, and is therefore considered by many clinicians and adjunct to treatment, rather than ...
As common as depression is—about one person in 10 experiences depression in any given year—it still eludes complete understanding. The trigger for depression can be almost any negative ...